Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lydie Meheus

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Future Oncology (London, England)|October 30, 2019
Journal retractions in oncology: a bibliometric studyPan Pantziarka, Lydie Meheus
Nature Reviews. Clinical Oncology|May 20, 2022
Ensuring completeness and timeliness of cancer treatment guidelinesGauthier Bouche, Lydie Meheus
Future Oncology (London, England)|December 12, 2019
Biased by design? Clinical trials and patient benefit in oncologyPan Pantziarka, Ciska Verbaanderd, Lydie Meheus
Cancer Immunology, Immunotherapy : CII|July 25, 2014
Inconsistencies and questionable reliability of the publication "immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophages-activating, GcMAF" by Yamamoto et alAna Ugarte, Gauthier Bouche, Lydie Meheus
The Lancet. Oncology|December 3, 2020
Drug repurposing in oncologyGauthier Bouche, Craig Gedye, Lydie Meheus, et al.
Frontiers in Pharmacology|February 21, 2020
On-Label or Off-Label? Overcoming Regulatory and Financial Barriers to Bring Repurposed Medicines to Cancer PatientsCiska Verbaanderd, Ilse Rooman, Lydie Meheus, et al.
Trends in Cancer|August 8, 2017
Repurposing Drugs in Oncology: Next StepsCiska Verbaanderd, Lydie Meheus, Isabelle Huys, et al.
Seminars in Cancer Biology|January 27, 2020
Repurposing drugs in oncology: From candidate selection to clinical adoptionPan Pantziarka, Ciska Verbaanderd, Isabelle Huys, et al.
European Journal of Cancer (Oxford, England : 1990)|April 23, 2021
The European Union and personalised cancer medicineJohn A Hickman, Ian F Tannock, Lydie Meheus, et al.
Lancet (London, England)|April 15, 2023
Drug evidence watch: a process to the benefit of public healthPan Pantziarka, Ian Roberts, Patricia Vandamme, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Future Oncology (London, England)|October 30, 2019
Journal retractions in oncology: a bibliometric studyPan Pantziarka, Lydie Meheus
Nature Reviews. Clinical Oncology|May 20, 2022
Ensuring completeness and timeliness of cancer treatment guidelinesGauthier Bouche, Lydie Meheus
Future Oncology (London, England)|December 12, 2019
Biased by design? Clinical trials and patient benefit in oncologyPan Pantziarka, Ciska Verbaanderd, Lydie Meheus
Cancer Immunology, Immunotherapy : CII|July 25, 2014
Inconsistencies and questionable reliability of the publication "immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophages-activating, GcMAF" by Yamamoto et alAna Ugarte, Gauthier Bouche, Lydie Meheus
The Lancet. Oncology|December 3, 2020
Drug repurposing in oncologyGauthier Bouche, Craig Gedye, Lydie Meheus, et al.
Frontiers in Pharmacology|February 21, 2020
On-Label or Off-Label? Overcoming Regulatory and Financial Barriers to Bring Repurposed Medicines to Cancer PatientsCiska Verbaanderd, Ilse Rooman, Lydie Meheus, et al.
Trends in Cancer|August 8, 2017
Repurposing Drugs in Oncology: Next StepsCiska Verbaanderd, Lydie Meheus, Isabelle Huys, et al.
Seminars in Cancer Biology|January 27, 2020
Repurposing drugs in oncology: From candidate selection to clinical adoptionPan Pantziarka, Ciska Verbaanderd, Isabelle Huys, et al.
European Journal of Cancer (Oxford, England : 1990)|April 23, 2021
The European Union and personalised cancer medicineJohn A Hickman, Ian F Tannock, Lydie Meheus, et al.
Lancet (London, England)|April 15, 2023
Drug evidence watch: a process to the benefit of public healthPan Pantziarka, Ian Roberts, Patricia Vandamme, et al.
Pageof 4